• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Sen­a­tors Wyden, Mur­ray launch No­var­tis probe: 'What Amer­i­ca has seen here rais­es the specter of cor­rup­tion'

7 years ago
Pharma

Celldex ax­es two more pro­grams to cut costs fol­low­ing glem­bat­u­mum­ab fail­ure; Zio­pharm stock slides on halt­ed brain ...

7 years ago
News Briefing

Jose Car­los 'JC' Gutiér­rez-Ramos hits the ex­it at Syn­log­ic; Rich Hey­man pass­es Oric reins to ex-Igny­ta CFO

7 years ago
Peer Review

Whisky, se­crets, and code names: be­hind-the-scenes of Takeda's $62B Shire bid - Bloomberg

7 years ago
Deals

Akari CEO Horn Solomon oust­ed af­ter al­leged­ly abus­ing the com­pa­ny cred­it card

7 years ago
People

La Jol­la grabs $125M roy­al­ty deal to back drug launch, fund R&D

7 years ago
Pharma

Trump is kick­ing the can down the road to­day, avoid­ing any tough pre­scrip­tions on drug pric­ing

7 years ago
Bioregnum
Opinion

As­traZeneca's star res­pi­ra­to­ry drug runs in­to an­oth­er wall with COPD, but it's not giv­ing up — yet

7 years ago
R&D

Akcea, Io­n­is win over most FDA ex­perts to their rare dis­ease drug volane­sors­en, vast­ly im­prov­ing odds of suc­cess

7 years ago
Pharma

Chi­na's CStone bags $260M Se­ries B for am­bi­tious I/O work, ex­pand­ing its list of mar­quee in­vestors

7 years ago
Financing
China

Astel­las signs Asian li­cens­ing deal with Aquinox; Ar­a­vive touts ear­ly-stage PoC

7 years ago
News Briefing

Eight years af­ter Eli Lil­ly dumped it, an up­start biotech has nabbed teplizum­ab and filed a $56M IPO to back a PhI­II ...

7 years ago
Financing
Startups

Hunt­ing a cure, Ex-No­var­tis ex­ec Bas­tiano San­na takes the reins at Cam­bridge di­a­betes start­up Sem­ma

7 years ago
People

Lit­tle vTv once again cir­cles sub­group num­ber, strug­gling to find some­thing good to say about failed Alzheimer's drug

7 years ago
R&D

Play­ing catch-up, Eli Lil­ly swoops in with $1.6B cash deal for Ar­mo Bio and its promis­ing PhI­II can­cer drug

7 years ago
Deals

Roche's big PhI­II Tecen­triq/Cotel­lic com­bo study for colon can­cer fails, dam­ag­ing Ex­elix­is shares

7 years ago
R&D

No­var­tis now says that it paid Trump's at­tor­ney $1.2M — and then throws ex-CEO Joe Jimenez un­der the bus

8 years ago
Bioregnum
Opinion

Fin­land's Faron ham­mered by sur­pris­ing piv­otal tri­al flop; CFO Si­mon Dinge­mans ex­its GSK in lead­er­ship makeover

8 years ago
News Briefing

Iron­wood pleas with in­vestors: Don't give us Alex Den­ner

8 years ago
Pharma

Genen­tech al­lies with a metage­nomics up­start in New York on a dis­cov­ery deal jam packed with biobucks

8 years ago
Pharma

Ex-Re­cep­tos CTO co-founds SD start­up Escient, launch­ing with $40M Se­ries A

8 years ago
Financing
Startups

Lipocine shares tum­ble (again) af­ter the FDA shows an­oth­er testos­terone ther­a­py the door

8 years ago
R&D

Temasek, cor­po­rate VCs buy in­to pre­scrip­tion dig­i­tal med hopes in Ak­il­i's $55M Se­ries C

8 years ago
Financing

Evelo Bio grabs $85M as the lat­est ear­ly-stage biotech de­buts on Nas­daq

8 years ago
Financing
First page Previous page 1028102910301031103210331034 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.